38.30 0.00 (0.00%)
After hours: 4:45PM EDT
|Bid||35.00 x 100|
|Ask||39.70 x 200|
|Day's Range||38.14 - 38.75|
|52 Week Range||35.33 - 46.80|
|PE Ratio (TTM)||10.14|
|Earnings Date||May 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.41|
In the news release, Women Treated with Hologic's NovaSure® Endometrial Ablation System in New Study Reported Higher Amenorrhea Rates than Those Treated with Minerva, issued 19-Apr-2018 by Hologic, Inc. ...
athenahealth's (ATHN) strong product portfolio, network expansion strategies and unique business model are likely to drive Q1 earnings.
Considering the ageing population, changing market dynamics, upbeat consumer sentiment and increased business investments, the Medical-Device sector appears to be in pink of health.
The hair and skin cosmetic procedure provider LightRx Face & Body announced a partnership Tuesday in which it will provide Hologic, Inc. (NASDAQ: HOLX )'s SculpSure non-invasive laser body contouring treatment ...
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 14. Over the last one-month, outflows of investor capital in ETFs holding HOLX totaled $14.78 billion.
On February 22, 2018, Hologic (HOLX) announced that it has entered into an agreement with the University of Minnesota to be an exclusive provider of Dexalytics: Teams software in North America. The partnership is aimed at providing groundbreaking body composition analysis software to the sports science and human performance industry. The software harnesses the body composition data provided by the DXA (dual X-ray absorptiometry) scans and compares them with the predetermined standards specific to the sport and position.
Hologic’s (HOLX) Viera system is a one-of-a-kind wireless, handheld breast ultrasound system. On February 28, 2018, Hologic announced that it will present its Viera system at the annual ECR (European Congress of Radiology) in Vienna along with seven of its other market-leading breast and skeletal health innovations. The list includes the company’s fastest and highest resolution breast tomosynthesis system, the 3Dimensions Mammography System, which was launched in Europe in September 2017.
On March 2, 2018, Hologic (HOLX) announced a global partnership with Royal Philips (PHG) to provide an integrated health solution for women comprised of diagnostic imaging modalities and advanced informatics along with screening, diagnosis, and treatment services. According to the agreement, some of the selected products from Hologic’s breast health portfolio will be available for Royal Philips to offer as part of its multi-modality deals for healthcare providers, hospitals, and more. The selected products include Hologic’s breast screening technologies, interventional radiology technologies, and its 3Dimensions Mammography System, the fastest breast tomosynthesis system in the market.
MARLBOROUGH, Mass. , April 3, 2018 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2018 on Wednesday, ...
On March 27, 2018, Hologic (HOLX) announced that its Clarity HD (high-definition) high-resolution 3D (three-dimensional) imaging and Intelligent 2D (two-dimensional) imaging technology has been approved by the FDA. The technologies are available for use on the company’s 3Dimensions Mammography System, the highest-resolution, fastest breast tomosynthesis system available in the market. Hologic’s 3Dimensions Mammography System was approved by the FDA in 2011.
Revenue, particularly in the Detection segment, continued to impress with very strong sales of the tomo (2D and 3D) products pushing total revenue up by 14% yoy. Detection product sales, up 100% yoy (pro-forma for ex-MRI), turned in the best quarter since Q3 2011 (when ICAD was still direct-selling MRI software) and crushed our number by 25%. While Q4 is typically ICAD’s strongest, the apparent accelerating adoption of the ‘legacy’ 2D and first-gen 3D tomo (GE-only) applications is obviously encouraging, particularly given the near-term launch of ICAD’s next-gen software.
When the market provides you with the opportunity to buy a strong business in a critical industry at a reasonable price, it's worth considering.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 14. Over the last one-month, outflows of investor capital in ETFs holding HOLX totaled $2.71 billion.
MARLBOROUGH, Mass., March 27, 2018 /PRNewswire/ -- Hologic, Inc. (HOLX) announced today that Clarity HD high-resolution 3D™ imaging and Intelligent 2D™ imaging technology have received PMA approval from the U.S. Food and Drug Administration (FDA) and are now available on the 3Dimensions breast tomosynthesis system. With these innovations, the system now provides higher resolution 3D™ images for radiologists, enhanced workflow for technologists, and a more comfortable mammography experience, with low-dose options, for patients. Hologic is the world leader in breast cancer screening and the pioneer behind the Genius™ 3D Mammography™ exam, first approved by the FDA in 2011 on the Company's first-of-its-kind 3D Mammography™ system.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 14. Index (PMI) data, output in the Healthcare sector is rising.
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In 2016, Erin was diagnosed with cervical cancer following her routine annual exam. Fortunately, her cancer was found early and was treated. As part of the new We Can Change This STAT initiative, Erin will share how her experience with cervical cancer has shaped her perspective today, including how she's maintaining her own health and encouraging other women to do the same by getting their annual exam.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 14. Over the last one-month, outflows of investor capital in ETFs holding HOLX totaled $16.97 billion.
LONDON, UK / ACCESSWIRE / March 6, 2018 / Active-Investors.com has just released a free research report on Hologic, Inc. (NASDAQ: HOLX ). If you want access to this report all you need to do is sign up ...
Hologic Inc.’s control of the market for 3D breast imaging in cancer screening is based on misuse of its patents and litigation, Fujifilm Holdings Corp. said in a lawsuit accusing its bigger rival of antitrust ...